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An international symposium on inherited epidermo-
lysis bullosa was held at the University of North Caro-
lina at Chapel Hill on April 25 - 26, 1994. All areas 
currently of clinical and research interest pertinent to 
this disease were discussed, ranging from basic epi-
demiologic issues to the definition of molecular de-
fects in each of the three major types of epidermolysis 
Sponsored in part by a conference grant from the National Institutes of Health, the goals of this meeting were to provide a intensive program encompassing a wide variety of clinical and research topics pertinent to inherited epi-dermolysis bullosa, and to provide a forum in which cut-
ting-edge findings from the laboratory could be presented alongside 
with focused discussions of ongoing clinical importance. A series of 
mini-symposia, discussion panels, and individual presentations were 
held. In addition, 64 posters, representing unpublished basic and 
clinical research, were prepared by participants and were made 
available for viewing and informal discussion throughout the course 
of this two-day meeting. Approximately 100 physicians and scien-
tists from the United States, Canada, the United Kingdom, France, 
Italy, Germany, Austria, Norway, Finland, the Netherlands, Israel, 
Japan, and Australia attended and participated in the symposium. 
SESSION I: CLINICAL AND EPIDEMIOLOGIC 
CONSIDERATIONS OF INHERITED 
EPIDERMOLYSIS BULLOSA 
Mini-Symposium I: Epidemiology of Inherited Epidermo-
lysis Bullosa Dr. Jo-David Fine (University of North Carolina at 
Chapel Hill) opened the symposium with an overview of the 
current scheme used by the National EB Registry (NEBR) for the 
diagnosis and subclassification of patients with inherited epidermo-
lysis bullosa. Advantages and limitations to this classification system 
were discussed. 
Dr. Lorraine Johnson (University of North Carolina at Chapel 
Hill) summarized much of the data generated to date from the 
NEBR. These data represented the efforts of investigators and col-
laborators at the four regional clinical centers (New York, Stanford, 
Chapel Hill, and Seattle) since inception of the project in 1986. As 
of December 1, 1994, comprehensive data had been compiled on 
1,764 epidermolysis bullosa patients residing within the continental 
United States. Data were analyzed collectively as well as after strati-
fication by NEBR clinical center, the latter done to search for possi-
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bullosa and the potential for gene therapy. A major 
focus of this meeting was the presentation of data col-
lected by the National Epidermolysis Bullosa Registry. 
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ble geographic differences in the composition of enrollees or for 
variation in the interpretation of specific findings by different 
groups of investigators. About half of all patients enrolled in the 
project were being followed by the Chapel Hill clinical center. 
Approximately 25% of all enrollees were assigned new epidermoly-
sis bullosa subtypes after comprehensive evaluation at one of the 
four clinical centers. One of the most significant findings noted was 
the rather profound overlap in many of the cutaneous findings, most 
notably scarring, milia, and nail dystrophy, across the four major 
epidermolysis bullosa groups; such overlap undoubtedly contrib-
uted to patient misclassification prior to the performance of sophis-
ticated diagnostic laboratory tests at the NEBR. Similarly, consider-
able overlap was observed in the frequencies of some extracutaneous 
findings, suggesting potential difficulties both in prognostication 
and in the specificity of diagnosis, if some of these findings are used 
for the latter purposes. Differences were also noted in the frequency 
of several cutaneous and extracutaneous findings across specific epi-
dermolysis bullosa subtypes (i.e., among Weber-Cockayne, 
Koebner, and Dowling-Meara variants of epidermolysis bullosa 
simplex). Significant interobserver variability was noted across the 
NEBR clinical centers when one prominent cutaneous feature 
(presence or absence of exuberant granulation tissue) was consid-
ered, whereas essentially little Or no variability was detected when 
another major clinical parameter, pseudo syndactyly, was assessed. 
Preliminary results were also presented of lifetable analyses across 
major epidermolysis bullosa types and subtypes for the development 
of pseudosyndactyly, tracheolaryngeal stenosis or obstruction, 
esophageal stenosis or obstruction, and premature death. 
Dr. Chirayath Suchindran (University of North Carolina at 
Chapel Hill), chief biostatistician for the NEBR, discussed several 
of the statistical techniques being employed for analysis and model-
ing of the extensive NEBR database. One of these techniques, clas-
sification and regression tree analysis (CART), employs a compli-
cated, iterative, mainframe computing approach whereby patients 
with as yet undiagnosed types of inherited epidermolysis bullosa can 
be assigned with reasonable accuracy into one of seven different 
epidermolysis bullosa subtyres or groups on the basis of the presence 
Or absence of one or more 0 a collection of selected clinical parame-
ters. Other biostatistical techniques discussed included lifetable 
analysis, hazards modeling (with fixed and time-dependent covar-
iates), and logistic regression. 
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Dr. Michael Tidman (University of Edinburgh, Scotland) 
presented preliminary data from the Epidermolysis Bullosa Registry 
recently established within Scotland. As of April 1994, 223 cases 
had been enrolled, approximately half having some form of epider-
molysis bullosa simplex. Of the dystrophic epidermolysis bullosa 
patients identified, three quarters were found to have autosom~1 
dominant transmission. Overall, the prevalence of epidermolySIS 
bullosa in Scotland was estimated to be about 45 cases per 1 million 
population, a figure closely approximating that reported (42/106 ) 
in Norway and nearly 1.5 and 2 times that reported in Northern 
Ireland and Finland, respectively. Interestingly, the prevalence of 
epidermolysis bullosa in Scotland is slightly less than one quarter 
and one tenth of that noted for neurofibromatosis and cystic fibrosis, 
respectively, within the same population. Data were also presented 
on the impact of epidermolysis bullosa on employment in Scotland. 
Similarly, Dr. Adrian Heagerty (North Staffordshire Hospital 
Centre, Stoke-on-Trent, England) discussed the demographics of 
his own epidermolysis bullosa patient cohort, including several 
large informative kindreds with the mottled pigmentation variant 
of epidermolysis bullosa simplex and a newly identified example of 
cicatricial junctional epidermolysis bullosa. 
Dr. Claudine Blanchet-Bardon (Hopital Saint-Louis, Paris, 
France) presented data on her experience with an epidermolysis 
bullosa patient population being followed in Paris. Although a for-
mal disease registry does not exist in France, 257 patients, 25% of 
whom represent recessive dystrophic epidermolysis bullosa, have 
been identified via the French epidermolysis bullosa association and 
are being followed in a multi-specialty research clinic setting. She 
reported that 17 of these patients, including individuals with both 
recessive dystrophic epidermolysis bullosa and the Dowling-Meara 
variant of epidermolysis bullosa simplex, had evidence of some type 
of glomerulonephritis. Four patients had multiple squamous cell 
carcinomas. 
Dr. Tobias Gedde-Dahl (University of Oslo, Norway) shared 
some of his extensive clinical and genetic experience with over 100 
and 69 Norwegian and Swedish kind reds, respectively, who are 
affected by epidermolysis bullosa, including patients with one rare 
subtype of epidermolysis bullosa simplex, the Ogna variant, which 
appears to exist only within a portion of Scandinavia. He noted 
striking differences in the incidence of specific epidermolysis bul-
losa subtypes within different regions of Scandinavia. Dr. I. Anton-
Lamprecht (University of Heidelberg, Germany) similarly 
presented data on those epidermolysis bullosa cases on whom inves-
tigative studies had been performed in Heidelberg. As of April 
1994, ultrastructural studies had been performed on 599 cases, rep-
resenting specimens not only from Germany but also from many 
other European sites. Nearly equal numbers of cases of simplex, 
junctional, and dystrophic epidermolysis bullosa were examined, 
including examples of Bart's syndrome from each of these three 
major epidermolysis bullosa groups. 
Dr. Hiroshi Shimizu (Keio University School of Medicine, 
Toyko, Japan) presented data on the prevalence of epidermolysis 
bullosa in Japan, based on a nationwide survey performed in 1983. 
Three-hundred ninety-three cases (epidermolysis bullosa simplex, 
48.2%; junctional epidermolysis bullosa, 6.0%; dominant dystro-
phic epidermolysis bullosa, 18.7%; recessive dystrophic epidermo-
lysis bullosa, 28.2%) were identified by questionnaire sampling 
within the departments of dermatology and pediatrics at 406 Japa-
nese hospitals. On the basis of this survey, the prevalence for all 
forms of epidermolysis bullosa in Japan was estimated at 670 - 920 
cases per 10,000 population, and the prevalences of epidermolysis 
bullosa simplex, junctional epidermolysis bullosa, dominant dystro-
phic epidermolysis bullosa, and recessive dystrophic epidermolysis 
bullosa were estimated to be approximately 340-470, 18-24, 
130-180, and 180- 250 cases per 10,000 population, respectively. 
Mini-Symposium II: Carcinogenesis and Inherited Epider-
molysis Bullosa Dr. Edison Liu (University of North Carolina 
at Chapel Hill) gave a presentation on many of the proposed mecha-
nisms of carcinogenesis, focusing on the molecular basis of some 
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malignancies, particularly myelogenous leukemias resulting from 
ras oncogene mutations, and discussed many of the epidemiologic 
ramifications of such findings. 
Dr. Fine next presented longitudinal data from the NEBR cohort 
on the prevalence and cumulative risk of epidermolysis bullosa pa-
tients developing one or more skin cancers. Data were stratified by 
major epidermolysis bullosa type and subtype for each of several 
different cancer types, including basal cell carcinoma, squamous cell 
carcinoma, malignant melanoma, and a group comprised of all 
other histologically distinct tumors. It was demonstrated that the 
risk of developing at least one squamous cell carcinoma in the set-
ting of recessive dystrophic epidermolysis bullosa was 72 times that 
seen in NEBR patients with epidermolysis bullosa simplex. Using 
lifetable analysis, it was further shown that squamous cell carcino-
mas were confined to patients with recessive dystrophic epidermo-
lysis bullosa, that they occurred more frequently in patients with the 
Hallopeau-Siemens subtype, and that they became a clinically seri-
ous concern on or after about age 20, with 23.7% and 51.0% of 
Hallopeau-Siemens patients at risk for this tumor by ages 25 and 35, 
respectively. It was also reported that the cumulative risk of malig-
nant melanoma in the Hallopeau-Siemens subtype was about 4% by 
age 12. 
Dr. John McGrath (St. Thomas' Hospital, London, England) 
reported on 31 squamous cell carcinomas that arose within about a 
third of a 35-member cohort of recessive dystrophic epidermolysis 
bullosa patients. In some instances, multiple tumors arose within 
individual patients. Most of these tumors arose in areas of chronic 
scaling or ulceration and were usually histologically well differen-
tiated, and almost all developed over bony prominences on the 
extremities. Worst clinical outcomes were usually associated with 
more poorly differentiated tumors. Dr. McGrath also reported on a 
recent immunohistochemical study on recessive dystrophic epider-
molysis bullosa-associated squamous cell carcinomas, using an an-
tibody specific for the p53 oncogene. Twenty-six percent of these 
tumors had immunohistochemical evidence of p53 expression, pri-
marily tumors that were moderately to poorly differentiated. Al-
though data were limited, these findings suggested that p53 expres-
sion might correlate with more aggressive biologic activity of these 
tumors. 
Dr. Stephen Tyring (University of Texas Medical Branch, Gal-
veston, TX) discussed very recent studies on DNA and RNA ex-
tracted from a small number of squamous cell carcinomas that arose 
in the skin of a few Hallopeau-Siemens patients. No human papillo-
maviruses were detected within these tumors. However, three of 
the four tumors had mutations detected within the p53 oncogene, 
suggesting a role for p53 oncogene mutations in the evolution of 
these tumors. Dr. Tyring also summarized a series of ill vitro immu-
nologic studies performed on peripheral blood cells from patients 
with each of the four major epidermolysis bullosa types. Marked 
diminution of natural killer cell activity was noted in patients with 
most severe disease activity, most notably those patients with the 
Hallopeau-Siemens subtype of recessive dystrophic epidermolysis 
bullosa. Similarly, the number of cells bearing markers for natural 
killer cells was decreased, and alterations were noted in cells bearing 
CD4+ and CD8+ markers. Interleukin-2 production was slightly 
reduced by those cells obtained from patients with junctional epi-
dermolysis bullosa and markedly decreased in both major forms of 
dystrophic epidermolysis bullosa. Interleukin-1 production was 
similarly diminished in these epidermolysis bullosa types. Itl vitro y-
but not a-interferon production was also reduced in junctional and 
dystrophic epidermolysis bullosa. In vitro production of tumor ne-
crosis factor a and tumor necrosis factor P was progressively dimin-
ished injunctional, dominant dystrophic, and recessive dystrophic 
epidermolysis bullosa patients. 
Mini-Symposium III: Therapy of Inherited Epidermolysis 
Bullosa Dr. Eugene A. Bauer (Stanford University) gave a histor-
ical overview on the use of phenytoin and retinoids in the manage-
ment of patients with recessive dystrophic epidermolysis bullosa. As 
he discussed, phenytoin was originally chosen for clinical trial due 
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to evidence of increased interstitial collagenase activity in this epi-
dennolysis bullosa subtype, and the hypothesized inhibition of this 
enzyme by phenytoin, based upon early in vitro studies. In further 
suppOrt of the use of phenytoin, it was more recently demonstrated 
that interstitial collagenase cleaves type VII collagen, the molecular 
target for genetic mutation in dystrophic epidermolysis bullosa. 
Whereas initial open clinical studies revealed a dose-dependent de-
crease in blister counts with increasing phenytoin serum levels, a 
subsequent double-blinded, crossover, placebo-controlled, multi-
center clinical trial failed to show any overall benefit. Retinoid acid 
was similarly considered for clinical trial in recessive dystrophic 
epidermolysis bullosa due to ill vitro data, suggesting that it also 
partially inhibited collagenase expression in a dose-dependent man-
ner and induced tissue inhibitor of metalloproteinases (thereby sec-
ondarily inhibiting collagenase activity). Similarly, ill vitro studies 
have suggested that retinoic acid may induce expression of one or 
more chains of nicein/kalinin, suggesting a potential role for reti-
noids in the treatment of junctional epidermolysis bullosa. How-
ever, in a very small, unpublished, open trial ofisotretino in in reces-
sive dystrophic epidermolysis bullosa, modest im.provement was 
noted but excessive side effects prevented its further use even when 
very low dosages of the drug were employed. On the bas is of these 
collective data, neither phenytoin nor any of the retinoids currently 
is being employed in the routine management of patients with any 
type of epidermolysis bullosa. 
Dr. A. Griswold Bevin, Jr. (University of North Carolina at 
Chapel Hill) gave a personal and historical overview of the surgical 
management of skin cancers in patients with severe generalized 
recessive dystrophic epidermolysis bullosa, emphasizing the roles of 
both definitive and palliative surgical measures. In addition, he re-
ported excell ent results with skin grafting in over 170 reconstruc-
tive procedures performed in this unique epidermolysis bullosa sub-
population. 
Dr. J. Timothy Wright (University of North Carolina at Chapel 
Hill) presented data from an ongoing prospective study on the na-
ture of oral manifestations in various types of epidermolysis bullosa. 
He reviewed differences, as stratified across the major epidermolysis 
bullosa types and subtypes, in the observed frequencies of soft tissue 
erosions, ulceration, scarring, milia, ankyloglossia, and microsto-
mia. Similarly, he presented data on the frequency of enamel hypo-
plasia and caries across all major epidermolysis bullosa types and 
subtypes. 
Dr. Andrew Lin (Rockefeller University) discussed some 8 years' 
experience with the use of autologous cultured keratinocyte grafts 
for the treatment of non-healing wounds in patients with severe 
junctional and recessive dystrophic epidermolysis bullosa. Al-
though repeated grafting was often required, lasting wound clo-
sures were achieved, thereby allowing for further reconstructive 
procedures to be performed, when indicated. Dr. John McGrath (St. 
Thomas' Hospital, London, England) then described his experience 
with the use of allogeneic cultured keratinocytes as skin grafts in ten 
patients with severe recessive dystrophic epidermolysis bullosa . 
When compared to non-grafted skin sites, no significant clinical 
benefits were obtained by the application of these allografts. 
Dr. Elizabeth Fenjves (SUNY at Stony Brook) gave the keynote 
address on gene therapy. Both ex vivo (using autologous keratino-
cytes) and i,·/ vivo approaches were described . A major limitation 
reported with the ill vivo technique is the current inability to specifi-
cally target the gene to a selected recipient cell type. Examples were 
given of specific genes that have been successfully transduced into 
keratinocytes in culture, of genes introduced into keratinocytes that 
have been measured in the systemic circulation, and of genes that 
appear to be at least temporarily stable with regard to their expres-
sion. Unfortunately, to date the latter phenomenon has been true 
only ill vitro; in vivo, this gene expression is only transient. Another 
technical problem yet to be overcome is how to get a gene to pene-
trate the stratum corneum. Alternatively, it has been shown that a 
gene can be injected intradermally, but the latter does not allow for 
the targeting of specific cells. A number of specific issues pertinent 
to epidermolysis bullosa and gene therapy were raised. For example, 
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in an autosomal dominant disorder like epidermolysis bullosa sim-
plex, it will be necessary to silence an existing gene, although it is 
not yet clear how this will be technically achievable. Finding a 
means whereby the exogenous gene can be selectively transported 
to its target cell will also be critical. In the case of keratinocytes, the 
target cell should be a stem cell, although little is yet known about 
this epidermal cell subpopulation. It is also unknown whether an 
inserted gene will be biologically active. 
A panel discussion was held on other therapeutic options in epi-
dermolysis bullosa. On the basis of the results of an ongoing study 
being conducted at Rockefell er University on a limited nl1l11ber of 
Hallopeau-Siemens patients, Dr. Lin recommended elective gas-
trostomy placement in those patients unable to take in reasonable 
amounts of nutrients orally, noting significant weight gains in those 
patients so treated . Dr. Bauer commented on a similarly positive 
response in gastrostomy-fed patients on both body weight and, in 
affected adolescents, the promotion of secondary sex changes. Dr. 
Anton-Lamprecht reported on the successful use ofballoon-assisted 
dilatation of the esophagus; similar benefit with mercury-weighted 
di lators was noted by Dr. Fine. Dr. Bauer briefly discussed the 
potential benefits and limitations to the use of topical transforming 
growth factor P in a disease, such as dystrophic epidermolysis bul-
losa, that is already associated with significant dermal fibrosis. Sev-
eral panel members also commented on the relative m.erits and risks 
of elective tracheostomy placement in junctional epidernlolysis 
bullosa children having evidence of early tracheolaryngeal disease 
activity. 
Mini-Symposium IV: Postnatal and Prenatal Diagnosis and 
Inherited Epidermolysis Bullosa Dr. Karen Holbrook (Uni-
versity of Florida) gave a detailed presentation on the morphogene-
sis of normal fetal human skin and the application of transmission 
electron microscopy in both postnatal and prenatal diagnosis of 
specific epidermolysis bullosa subtypes. Over 40 such fetuses have 
been evaluated by her former laboratory in Seattle; no errors in 
diagnosis have occurred, and only a minority of these fetuses at risk 
for epidermolysis bullosa were shown to be affected . She also com-
mented on the interesting morphologic finding of macrophagic-ap-
pearing cells in the amniotic fluid of mothers carrying fetuses af-
fected with recessive dystrophic epidermolysis bullosa. 
. Dr. Jo-David Fine (University of North Carolina at Chapel Hill) 
discussed the role of immunofluorescence antigenic mapping and 
the findings of selected skin basement membrane-specific monoclo-
nal antibody studies in both the postnatal and prenatal diagnosis of 
major epidermolysis bullosa types and subtypes. Data were 
presented confirming that antigenic mapping is as accurate and 
sensitive as transmission electrO!l microscopy in distinguishing 
among simplex, junctional, and dystrophic forms of epidermolysis 
bulIosa. Sensitivity and specificity of diagnosis were reported for 
monoclonal antibodies to type VII colIagen (LH 7: 2 epitope), ka-
linin/nicein (GB3), and uncein (19-DEJ-1), both when used singly 
and in combinations. In general, absence or diminution of type VII 
colIagen staining was both sensitive and specific for recessive dys-
trophic epidermolysis bullosa, although further delineation of spe-
cific recessive dystrophic epidermolysis bullosa subtypes resulted in 
considerable reduction in both sensitivity and specificity. Whereas 
abnormaluncein staining was a highly sensitive (i.e., 100%) marker 
for junctional epidermolysis bullosa, the finding was not totally 
specific, because a minority of recessive dystrophic epidermolysis 
bullosa specimens also revealed similar or identical findings. Simi-
larly, although absence of kalinin/ l1icein was highly specific for 
junctional epidermolysis bulIosa , particularly of the Herlitz variant, 
the sensitivity of this finding was weak. However, combining the 
results obtained with antibodies to uncein and kalinin/nicein led to 
findings which were both highly sensitive and specific for junc-
tional epidermolysis bullosa. 
Dr. Sherman Elias (University of T ennessee, Memphis) gave a 
detailed lecture on the surgical aspects of prenatal diagnosis of in-
herited epidermolysis bullosa. Beginning with a historical overview 
of fetoscopy-directed skin biopsies, Dr. Elias then discussed more 
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recent sampling techniques employing smaller, flexible, biopsy for-
ceps that are inserted into the amniotic cavity via a small bore plastic 
catheter and precisely guided by two-dimensional ultrasound visu-
alization. Seventeen of the latter biopsies have now been performed 
in Memphis without any resultant fetal wastage; in every case, the 
presence or absence of inherited epidermolysis bullosa was correctly 
predicted on the basis of the appearance of the surgical samples so 
obtained. Other diagnostic prenatal sampling approaches poten-
tially applicable to inherited epidermolysis bullosa were discussed, 
including amniocentesis and chorionic villus sampling; advantages 
and limitations of each were discussed. Finally, an overview was 
given on recent attempts at the prenatal diagnosis of aneuploidy 
using fetal nucleated erythrocytes, identified and fluorescence acti-
vated cell sorter-isolated by the presence of the CD71 transferrin 
receptor and glycophorin-A, which can be isolated from maternal 
blood samples, counterstained for the presence of fetal hemoglobin, 
and then studied using specific DNA probes that collectively can 
identify about 95% of aU major chromosome anomalies. 
Dr. Robin Eady (St. Thomas' Hospital, London, England) re-
ported on over 150 prenatal diagnostic studies, some of which rep-
resented subsequent pregnancies in the same mothers, and noted 
that his group is now frequently obtaining fetal skin samples at 
earlier gestational times than in the past (i.e., 15 rather than 18 
weeks). He also commented on the presence of remnants of kerati-
nocyte plasma membranes along the bases of cleavage planes in 
specimens from fetuses affected with junctional epidermolysis bul-
losa in association with pyloric atresia. Given the normal expression 
of nicein/kalinin (via GB3 monoclonal antibody) in such tissue, he 
questioned whether these patients had a form of pseudo-junctional 
epidermolysis bullosa. Dr. Blanchet-Bardon reported on 86 prena-
tal diagnostic studies, 48 fetuses of which were at risk for the Herlitz 
variant of junctional epidermolysis bullosa. Similar to the experi-
ences of other groups performing such studies, both sensitivity and 
specificity were 100% (i.e., no false-positive or false-negative stud-
ies), and' about 30% of her cases subsequently were shown to be 
affected. She also reported on the successful performance of prenatal 
studies on chorionic villi from three mothers at risk and trophoblast 
sampling from an additional one, using molecular biologic probes. 
Dr. Shimizu commented on his experience with prenatal diagnosis 
in a limited number of cases at risk in Japan. Dr. Anton-Lamprecht 
discussed her experience with 106 prenatal diagnostic studies for 
epidermolysis bullosa. She reported high sensitivity and specificity 
for several known morphologic markers of disease (i.e., hypoplastic 
hemidesmosomes and junctional epidermolysis bullosa). She also 
commented on the morphologic reasons chorionic villi cannot be 
used reliably for the ultrastructural prenatal diagnosis of inherited 
epidermolysis bullosa at even 11 gestational weeks. Dr. Holbrook 
commented on some of the potential technical problems associated 
with the evaluation of fetal skin biopsy samples, including the fre-
quent visualization of artifactual intraepidermal clefts associated 
with the surgical technique, the occasional harvesting of fetal mem-
branes rather than skin, and several morphologic problems that may 
arise as a result of inadequate fixation. 
Dr. Jouni Uitto (Jefferson Medical College) gave a presentation 
on the potential application of molecular biologic techniques to the 
prenatal diagnosis of selected epidermolysis bullosa types. He dis-
cussed the advantages of molecular studies over those currently 
employed using fetal skin samples, as well the advantages associated 
with harvesting DNA from chorionic villi rather than from amni-
otic cells obtained via amniocentesis. He then presented examples of 
a few recently performed studies (i.e., evaluation of a fetus at risk for 
Hallopeau-Siemens recessive dystrophic epidermolysis bullosa via 
linkage analysis using markers for the type VII collagen gene). He 
also discussed the exciting potential of preimplantation diagnosis 
and the subsequent selection and implantation of unaffected em-
bryos, following successful performance of ill vitro fertilization. 
SESSION II: THE BASIC SCIENCE OF INHERITED 
EPIDERMOLYSIS BULLOSA 
Dr. Robert A. Briggaman (University of North Carolina at Chapel 
Hill) provided a historical perspective on those ultrastructural ab-
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normalities of the dermoepidermal junction that have been asso-
ciated with specific epidermolysis bullosa types and subtypes. He 
further commented on many of the potential problems that may 
arise in the diagnosis, classification, and subclassification of epider-
molysis bullosa using exclusively morphologic findings as markers 
of disease, emphasizing both the influence of genetic heterogeneity 
and the likely variability of correlation between clinical phenotype 
and specific structural abnormalities. Drs. Tidman and Eady then 
reviewed and summarized their data obtained from the morpho-
metric analysis of specific structures along the dermoepidermal 
junction in both normal and epidermolysis bullosa skin. Dr. Eady 
also presented more recent ultrastructural work employing an im-
munogold labeling technique, demonstrating semi-quantitative 
differences in the numbers of anchoring fibrils in patients with 
different subtypes of recessive dystrophic epidermolysis bullosa. He 
also discussed findings from a series of elegant morphometric stud-
ies focused on the definition of quantitative differences within the 
epidermis of specific structural features (i.e., keratin filaments), both 
in different layers of the skin and in different regional body sites. 
The focus of the symposium then turned toward data derived 
from antibody probes directed at specific skin basement membrane 
proteins. Dr. Heagerty began by reviewing the collective data on 
staining of epidermolysis bullosa skin specimens with the anti-type 
VII collagen monoclonal antibody, LH 7 : 2. He contrasted the re-
ported abnormal staining of LH 7: 2 to two previously reported 
monoclonal antibody probes for dystrophic epidermolysis bullosa, 
KF-1 and AF1/ AF2, and then discussed the parallel findings ob-
served with LH20Sp, an anti-human sperm fibrous sheath mono-
clonal antibody that also binds along the human dermoepidermal 
junction, most likely to an epitope of type VII collagen. Finally, Dr. 
Heagerty discussed the ontogeny of each of these antigens in human 
fetal skin and then demonstrated how each associated antibody has 
been successfully employed in prenatal diagnosis. 
Dr. Guerrino Meneguzzi (University of Nice, France) next dis-
cussed nicein/kalinin, a laminin isoform, and one of two recently 
recognized components of the anchoring filament. The differences 
in staining of skin from different junctional epidermolysis bullosa 
subtypes with the GB3 monoclonal antibody were summarized. He 
described the biochemical and molecular characterization of each of 
the three nicein/kalinin subunits and cited the existence of antibod-
ies specific for each. Examples were given of altered expression 
(both in mRNA and actual protein production) of individual ni-
cein/kalinin chains in some junctional epidermolysis bullosa pa-
tients. He reported that nicein/kalinin is synthesized in normal 
teeth by enamel-producing ameloblasts. Thus, he hypothesized that 
the enamel defect observed characteristically in all junctional epi-
dermolysis bullosa patients reflects altered expression of this pro-
tein. He also reported the presence of one of the B chains of nicein 
and the transient detection of its A chain in the choroid plexus and . 
spinal cord, respectively, of lower vertebrates. 
Dr. Fine reported on the further characterization of uncein (19-
DEJ-l), the first protein documented immu'~ohistochemically to be 
an anchoring filament protein and the only protein undetectable 
with the dermoepidermal junction of any junctional epidermoly-
sis bullosa skin specimen, regardless of disease subtype. As with 
nicein/kalinin, three uncein subunits have been detected. A product 
of the keratinocyte, uncein was shown to be present in cultures of 
keratinocyte monolayers within and on their cell membranes 
whereas nicein/kalinin was detectable only underneath and be-
tween these cells. Confocal microscopy studies confirmed these 
strikingly distinctive localization patterns for the two proteins. Fur-
thermore, he reported that uncein, but not nicein/kalinin, co-loca~ 
lized with two known hemidesmosome-associated proteins,a6p4 
integrin and bullous pemphigoid antigen-I. He noted by both im-
munofluoresence and immunoprecipitation studies that uncein ap-
peared to be trapped intracytoplasmically in cultured keratinocytes 
from a patient with generalized non-Herlitz junctional epidermo-
lysis bullosa, whereas nicein/kalinin expression appeared to be un-
altered. 
Dr. Bauer spoke on the role of matrix metalloproteinases in epi-
dermolysis bullosa, first reviewing hI vivo and ill vitro data on tissue 
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collagenase. Cytokines up-regulating and down-regulating matrix 
metalloproteinases were described. Similarly, the postulated role of 
jUM andJos in the regulation of collagenase expression was discussed. 
Data were presented on the increased expression of both tissue col -
lagenase and stromelysin-1 by recessive dystrophic epidermolysis 
bullosa fibroblasts, in the face of normal levels of tissue inhibitor of 
metalloproteinases . 11-1 vitro studies were presented to demonstrate 
that tissue collagenase does degrade type VII collagen. Finally, Dr. 
Bauer discussed the possibility of antisense inhibition of gene ex-
pression of interstitial collagenase. 
Mini-Symposium V: Molecular Biology of Inherited Epi-
dermolysis Bullosa The first part of this mini-symposium, fo-
cused on epidermolysis bullosa simplex, was chaired by Dr. Elaine 
Fuchs (University of Chicago). Dr. Fuchs began by reviewing the 
structural organization of keratin filaments. She then summarized 
the results of a series of deletion mutagenesis experiments aimed at 
determining the influence of mutations within different regions of 
the keratin 14 molecule on the subsequent formation of a stable 
keratin filament network. Subsequent transgenic mouse models, 
using different keratin 14 gene mutations, revealed that some of 
these mutations resulted in phenotypes having intraepidermal blis-
ter formation and mechanical fragility, reminiscent of some epider-
molysis bullosa simplex subtypes. Introduction of a mutation 
known to be a severe disrupter of keratin fil ament assembly resulted 
in clumping of keratin filaments similar to that observed in the 
Dowling-Meara variant, whereas milder gene mutations were asso-
ciated with ultrastructural findings within basilar keratinocytes 
consistent with those observed in the Weber-Cockayne subtype of 
epidermolysis bullosa simplex. Immunofluorescence studies ofker-
atinocytes from patients with the Dowling-Meara variant demon-
strated a collapsed keratin network when examined with antibodies 
to keratins 5 and 14, and keratins extracted from these cells failed to 
assemble normally into filaments. Subsequently several mutations 
were identified in DNA from patients with Dowling-Meara and 
Weber-Cockayne patients within the same regions of the keratin 14 
gene that were predicted by transgenic mouse experiments. Dr. 
Fuchs then summarized data from several other laboratories on the 
different sites of mutations within either keratin 5 or 14 genes in 
patients with each of the major epidermolysis bullosa simplex sub-
types, noting that the location of these mutations correlated well 
with the relative severity of disease activity observed in different 
epidermolysis bullosa subtypes. She also noted that site-directed 
mutagenesis experiments in cu ltured keratinocytes resulted in kera-
tin staining patterns identical to those observed in cell s cultured 
from different epidermolysis bullosa simplex subtypes. Finally she 
summarized studies on epidermolytic hyperkeratosis, in which mu-
tations recently have been mapped in the keratin 1 or 10 genes, 
analogous to those observed in epidermolysis bullosa simplex. 
Dr. Birgitte Lane (University of Dundee, Scotland) presented 
data from her laboratory on keratin 5 gene mutations in epidermo-
lysis bullosa simplex, demonstrating relative clustering of the muta-
tions within selected regions of the gene. In the case of Weber-
Coc.!<ayne epidermolysis bullosa simplex, she postulated that the 
structural instability of the resultant keratin molecules might be 
seconda'ry to the creation of new phosphorylation sites. Dr. Irene 
Leigh (London Hospital Medical Hospital, London, England) dis-
cu.ssed mutations that she has detected within keratin 1 or 10 genes, 
which encode for keratins present with suprabasilar keratinocytes, 
in several different kindreds with epidermolytic hyperkeratosis, and 
summarized data from others on mutations in keratin 9, a protein 
confined to palms and soles, in patients with inherited palmoplantar 
keratodermas. She also commented on recent studies in ichthyosis 
buUosa of Siemens that demonstrated mutations in the keratin 2 
gene. Dr. Adrian Heagerty discussed preliminary molecular studies 
on several kind reds with the syndrome of epidermolysis bullosa 
simplex associated with mottled pigmentation and punctate kerato-
derma. Dr. Karen Stephens (University of Washington) reported 
on tJle very unusual presence of homozygous dominant disease in a 
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large kindred with epidermolysis bullosa simplex of the Koebner 
variety. Linkage analysis and gene sequencing confirmed the muta-
tion to reside within the keratin 5 gene. Dr. Alain Hovnanian Gohn 
Radcliffe Hospital, Oxford, England) presented an example of a 
unique deletion mutation in keratin 5 in a patient with the Dow-
ling-Meara subtype of epidermolysis bullosa simplex. 
The second portion of this mini-symposium was directed toward 
studies focused on the elucidation of genetic defects in dystrophic 
epidermolysis bullosa. Dr. Angela Christiano Gefferson Medical 
College} began by discussing the structure of the gene for type VII 
collagen. She then described frameshift illutations in recessive dys-
trophic epidermolysis bullosa that resulted in premature termina-
tion codons and truncation of the type VII collagen. She also noted 
that electron microscopic findings suggest that carriers for this par-
ticular epidermolysis bulJosa subtype have approximately 50% of 
the number of anchoring fibrils observed in genetically unaffected 
individuals. In contrast to the findings observed in recessive dystro-
phic epidermolysis bullosa, in a large Finnish dominant dystrophic 
epidermolysis bullosa kindred she demonstrated the presence of a 
heterozygous substitution mutation, corresponding to the triple he-
hcal domain of the molecule, within the type VII collagen gene. On 
the basis of data generated on several other informative kind reds, 
she postulated that the generation of truncated polypeptides of type 
VII collagen results in the severe HalJopeau-Siemens form of reces-
sive dystrophic epidermolysis bulJosa, whereas assembly interfer-
ence within the NC-2 domain and triple helix disruption may ac-
count for disease in mitis recessive dystrophic epidermolysis bullosa 
and dominant dystrophic epidermolysis bullosa, respectively. 
Dr. Alain Hovanian reported on the detection of premature ter-
mination codons within the collagenous domain in a minority of 
patients studied who represent the Hallopeau-Siemens subtype of 
recessive dystrophic epidermolysis bulJosa. Dr. Leena Bruckner-
T~derman (University of Munster, Germany) described a patient 
WIth recessive dystrophic epidermolysis bulJosa in whom com-
pound heterozygous mutations within the type VII collagen gene 
were present; one resulted in a deletion, whereas the second repre-
sented an amino acid substitution. 
The final section of this mini-symposium was directed toward 
molecular defects and junctiona l epidermolysis bullosa. Dr. Tobias 
G~dde-Tobias described linkage studies on a series of junctional 
epIdermolysis bullosa patients from Scandinavia; in this well-char-
acterized study population, data suggested that some (i.e., inversa 
junctional epidermolysis bullosa patients) but not all junctional epi-
dermolysis bullosa patients may be linked to mutations within the 
laminin {32 gene. Dr. Jouni Uitto reported the identification of a 
mutation in the gene encoding for either of two of the three sub-
units of kalinin in two patients with junctional epidermolysis bul-
losa. In one kindred, having non-Herlitz disease, a homozygous 
lI1-frame exon deletion in the LAMB2 gene occurred. In a kindred 
with Herlitz disease, a premature termination codon resulted from a 
mutation within the LAMB3 gene. He also reported on four pa-
tients, collectively representing both Herlitz and non-Herlitzjunc-
tional epidermolysis bullosa, who were shown to have mutations 
within the LAMC2 gene ofkalinin, three of which led to premature 
termination codons. Finally, Dr. Guerino Meneguzzi described 
1ll1kage analysis studies consistent with LAMC2 gene mutation in a 
large informative family with Herlitzjunctional epidermolysis bul-
losa; direct sequencing revealed a point mutation that led to prema-
ture termination codon. He also described other mutations, includ-
ing exon skipping in one, within the same gene in a few other 
patients with Herlitz junctional epidemlolys is bullosa. 
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